Codexis Past Earnings Performance
Past criteria checks 0/6
Codexis's earnings have been declining at an average annual rate of -37.7%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 3.5% per year.
Key information
-37.7%
Earnings growth rate
-34.1%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 3.5% |
| Return on equity | -84.6% |
| Net Margin | -96.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Codexis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 64 | -62 | 54 | 0 |
| 30 Jun 24 | 61 | -76 | 53 | 0 |
| 31 Mar 24 | 74 | -65 | 51 | 0 |
| 31 Dec 23 | 70 | -76 | 53 | 0 |
| 30 Sep 23 | 74 | -82 | 53 | 0 |
| 30 Jun 23 | 99 | -57 | 55 | 0 |
| 31 Mar 23 | 116 | -48 | 52 | 0 |
| 31 Dec 22 | 139 | -34 | 52 | 0 |
| 30 Sep 22 | 133 | -31 | 52 | 0 |
| 30 Jun 22 | 135 | -19 | 51 | 0 |
| 31 Mar 22 | 122 | -21 | 54 | 0 |
| 31 Dec 21 | 105 | -21 | 49 | 0 |
| 30 Sep 21 | 101 | -15 | 46 | 0 |
| 30 Jun 21 | 83 | -23 | 42 | 0 |
| 31 Mar 21 | 72 | -25 | 37 | 0 |
| 31 Dec 20 | 69 | -24 | 35 | 0 |
| 30 Sep 20 | 67 | -21 | 34 | 0 |
| 30 Jun 20 | 70 | -14 | 33 | 0 |
| 31 Mar 20 | 68 | -14 | 32 | 0 |
| 31 Dec 19 | 68 | -12 | 32 | 0 |
| 30 Sep 19 | 66 | -12 | 31 | 0 |
| 30 Jun 19 | 61 | -14 | 30 | 0 |
| 31 Mar 19 | 62 | -11 | 30 | 0 |
| 31 Dec 18 | 61 | -11 | 29 | 0 |
| 30 Sep 18 | 66 | -9 | 30 | 0 |
| 30 Jun 18 | 59 | -18 | 31 | 0 |
| 31 Mar 18 | 56 | -20 | 30 | 0 |
| 31 Dec 17 | 50 | -23 | 29 | 0 |
| 30 Sep 17 | 38 | -29 | 28 | 0 |
| 30 Jun 17 | 43 | -18 | 25 | 0 |
| 31 Mar 17 | 49 | -9 | 25 | 0 |
| 31 Dec 16 | 49 | -9 | 25 | 0 |
| 30 Sep 16 | 50 | -5 | 24 | 0 |
| 30 Jun 16 | 53 | -1 | 25 | 0 |
| 31 Mar 16 | 43 | -9 | 24 | 0 |
| 31 Dec 15 | 42 | -8 | 22 | 0 |
| 30 Sep 15 | 44 | -5 | 21 | 0 |
| 30 Jun 15 | 34 | -15 | 21 | 0 |
| 31 Mar 15 | 35 | -18 | 21 | 0 |
| 31 Dec 14 | 35 | -19 | 22 | 0 |
| 30 Sep 14 | 31 | -29 | 22 | 0 |
| 30 Jun 14 | 27 | -34 | 23 | 0 |
| 31 Mar 14 | 28 | -38 | 25 | 0 |
| 31 Dec 13 | 32 | -41 | 27 | 0 |
Quality Earnings: 4QK is currently unprofitable.
Growing Profit Margin: 4QK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4QK is unprofitable, and losses have increased over the past 5 years at a rate of 37.7% per year.
Accelerating Growth: Unable to compare 4QK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4QK is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (5.4%).
Return on Equity
High ROE: 4QK has a negative Return on Equity (-84.59%), as it is currently unprofitable.